Burning Rock Biotech Limited has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer's growing portfolio of precision cancer therapies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 USD | +0.29% |
|
-4.63% | -26.88% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
26.15 EUR | -1.89% | +0.04% | 27.5B | ||
6.8 USD | +0.29% | -4.63% | 69.76M | ||
1st Jan change | Capi. | |
---|---|---|
-26.88% | 69.76M | |
-18.39% | 8.53B | |
+65.89% | 4.26B | |
+6.18% | 2.71B | |
-1.93% | 2.63B | |
-57.14% | 1.72B | |
-19.16% | 1.67B | |
-20.01% | 1.45B | |
+15.38% | 1.19B | |
-50.40% | 1.01B |
- Stock Market
- Equities
- BNR Stock
- News Burning Rock Biotech Limited
- Bayer and Burning Rock Biotech Limited Collaborates to Increase Patient Access to Precision Cancer Medicines